Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Miranda-Filho, 2018, Epidemiological patterns of leukaemia in 184 countries: a population-based study, Lancet Haematol, 5, e14, 10.1016/S2352-3026(17)30232-6 Byrd, 2013, Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, 369, 32, 10.1056/NEJMoa1215637 Byrd, 2016, Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia, N Engl J Med, 374, 323, 10.1056/NEJMoa1509981 Roberts, 2016, Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia, N Engl J Med, 374, 311, 10.1056/NEJMoa1513257 Jain, 2019, Ibrutinib and venetoclax for first-line treatment of CLL, N Engl J Med, 380, 2095, 10.1056/NEJMoa1900574 Al-Sawaf, 2021, Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials, Leukemia, 35, 169, 10.1038/s41375-020-0797-x Eyre, 2015, Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome, BMC Cancer, 15, 52, 10.1186/s12885-015-1048-9 Rossi, 2018, Biology and treatment of Richter syndrome, Blood, 131, 2761, 10.1182/blood-2018-01-791376 Eyre, 2016, NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome, Br J Haematol, 175, 43, 10.1111/bjh.14177 Tsimberidou, 2006, Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, 24, 2343, 10.1200/JCO.2005.05.0187 Davids, 2017, Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy, Proc Am Soc Clin Oncol, 35 Tsimberidou, 2008, Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia, J Clin Oncol, 26, 196, 10.1200/JCO.2007.11.8513 Ding, 2017, Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL, Blood, 129, 3419, 10.1182/blood-2017-02-765685 Thompson, 2015, Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens, Cancer, 121, 3612, 10.1002/cncr.29566 Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800 Hillmen, 2016, Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE-CL-001 clinical study, Blood, 128, 60, 10.1182/blood.V128.22.60.60 Davids, 2020, A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome, Proc Am Soc Clin Oncol, 38 Condoluci, 2021, Richter Syndrome, Curr Oncol Rep, 23, 26, 10.1007/s11912-020-01001-x Appleby, 2019, BMC Cancer, 19, 471, 10.1186/s12885-019-5717-y Tsimberidou, 2013, Phase I–II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome, Clin Lymphoma Myeloma Leuk, 13, 568, 10.1016/j.clml.2013.03.012 Langerbeins, 2014, Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation, Am J Hematol, 89, E239, 10.1002/ajh.23841 Gardner, 2014, ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma, Cancer Res, 74 Furman, 2021, Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies, Leukemia, 35, 3201, 10.1038/s41375-021-01252-y Eyre, 2017, An update for Richter syndrome—new directions and developments, Br J Haematol, 178, 508, 10.1111/bjh.14700 Brown, 2018, Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL, Leukemia, 32, 83, 10.1038/leu.2017.175 Kipps, 2019, Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia, Clin Lymphoma Myeloma Leuk, 19, 715, 10.1016/j.clml.2019.07.004 Kittai, 2020, Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome, Blood Adv, 4, 4648, 10.1182/bloodadvances.2020002783 Soilleux, 2016, Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review, Histopathology, 69, 1066, 10.1111/his.13024